Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Rheumatology Drug Updates: Abaloparatide Promising for Osteoporosis, Plus Secukinumab for Ankylosing Spondylitis

  |  Issue: October 2016  |  

Michele B. Kaufman, PharmD, CGP, RPh, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

  1. Radius Health Inc. News release: JAMA publishes positive phase III data for abaloparatide in postmenopausal women with osteoporosis. 2016 Aug 16.
  2. Miller PD, Hattersley G, Riis BJ, et al. Effect of abaloparatide vs. placebo on new vertebral fractures in postmenopausal women with osteoporosis: A randomized clinical trial. JAMA. 2016 Aug 16;316(7):722–733.
  3. Staff. NICE draft guidance recommends new drug for people with ankylosing spondylitis. FirstWord Pharma. 2016 Aug 8.
  4. Yokota S, Itoh Y, Morio T, et al. Tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: Results from 1 year of post-marketing surveillance follow-up of 417 patients in Japan. Ann Rheum Dis. 2016 Sep;75(9):1654–1660.

Related Articles

    FDA Approves Abaloparatide to Treat Men with Osteoporosis & a High Risk of Fracture

    In late December, the FDA approved subcutaneous abaloparatide for the treatment of men with osteoporosis at a high risk of fracture. This approval is based on a placebo-controlled study that showed abaloparatide led to significant increases in bone mineral density of the lumbar spine, total hip and femoral neck. Abaloparatide was approved in April 2017 for the treatment of postmenopausal women with osteoporosis at high risk for fracture.